The mission of the PNA is to improve the quality of life of those affected by Parkinson’s disease through supporting community outreach programs offered through the Muhammad Ali Parkinson Center (MAPC) in Phoenix, AZ.
June 28, 2017 the PNA board presented this check to the MAPC to continue our commitment and support to the Arizona Parkinson community. Thanks to everyone that has supported us!!
Accepting the donation check is Dr. Holly Shill. Pictured with Dr. Shill are board members, Ruby Rendon, Leta Sproule, Jill Wallace, Melanie Wright and Lee Crozier.
The National Parkinson Foundation, a division of the Parkinson Foundation recognized the efforts of the Muhammad Ali Parkinson Center at Barrow Neurological Institute and National Parkinson Foundation Center of Excellence in providing a powerful caregiver program.
Visit www.parkinson.org to learn more about the National Parkinson Foundation and the Center of Excellence recognition of the MAPC's caregiver programs led by social worker Nancy Bivins, MSW.
The Phoenix Mayor's Commission on Disability Issues has invited the Tremble Clefs and Voces Unidas Parkinson singing groups to perform at their 2017 Annual Award Banquet.
What an exciting opportunity to showcase the talent of the Parkinson's community as well as raise awareness about the disease. Want to learn more about the Tremble Clefs and Voces Unidas click here.
VANCOUVER — Researchers are using smartphones to collect and analyze data on motor symptoms and mobility of patients with early Parkinson's disease (PD).The technology reflects how well patients with PD are functioning and might eventually be used in clinical trials to determine whether therapeutic interventions are working, Michael Lindemann, PhD, Roche Pharma Research and Early Development, Basel, Switzerland, told Medscape Medical News.
VANCOUVER — A new inhaled formulation of levodopa effectively addresses "off" periods in patients with Parkinson's disease (PD), results of a phase 3 study have shown.The study demonstrated significantly greater improvement in Unified Parkinson's Disease Rating Scale (UPDRS) motor scores for patients using this new agent (CVT-301) compared with those using a placebo.
Parkinson’s disease, which affects more than 10 million people worldwide, is a neurological disorder that occurs as a result of the death of nerve cells in the brain that produce dopamine. The loss of dopamine production in the brain can lead to tremors, balance problems, stiff facial expressions and muffled speech, among other things. How does Parkinson’s disease affect the body? The mind? How does having a progressive disease affect families? Listen to the stories of seven men and women with Parkinson’s disease.